Subject    :    [2017 Feb;41(1)] Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
Writer KDA
Date 2017-03-23 10:35:58 Hit 5,963
Diabetes Metab J. 2017 Feb;41(1):69-74. English. Published online Dec 26, 2016.  https://doi.org/10.4093/dmj.2017.41.1.69 
Copyright © 2017 Korean Diabetes Association
   
Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
Kun-Ho Yoon,1 Elise Hardy,2 and Jenny Han3
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
2AstraZeneca, Gaithersburg, MD, USA.
3Pharmapace, San Diego, CA, USA.
Corresponding author: Kun-Ho Yoon. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea. Email: yoonk@catholic.ac.kr 
 
Received April 09, 2016; Accepted July 18, 2016.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

 
Abstract
Background

The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in Korea. Clinical studies in patients with T2DM have shown that combining the glucagon-like peptide-1 receptor agonist exenatide twice daily with basal insulin is an effective glucose-lowering strategy. However, these studies were predominantly conducted in non-Asian populations.

Methods

We conducted a subgroup analysis of data from a multinational, 30-week, randomized, open-label trial to compare the effects of exenatide twice daily (n=10) or three times daily mealtime insulin lispro (n=13) among Korean patients with T2DM inadequately controlled (glycosylated hemoglobin [HbA1c] >7.0%) on metformin plus optimized insulin glargine.

Results

Exenatide twice daily and insulin lispro both reduced HbA1c (mean −1.5% and −1.0%, respectively; P

Conclusion

This analysis found treatment with exenatide twice daily improved glycemic control without weight gain in Korean patients with T2DM unable to achieve glycemic control on metformin plus basal insulin.

   
Keywords:
Diabetes mellitus, type 2; Exenatide; Insulin lispro
 

Articles - Reviews in DMJ
No. Subject Date Hit ↓
197 [2017 Jun;41(3)] Satisfaction Survey on Information Technology-Based... 2017-07-06 6,672
196 [2017 Jun;41(3)] The Effect of 12 Weeks Aerobic, Resistance, and Com... 2017-07-06 6,649
195 [2017 Jun;41(3)] Impact of Gender on the Association between Low Ser... 2017-07-06 6,515
194 [2017 Jun;41(3)] Physician-Directed Diabetes Education without a Med... 2017-07-06 6,195
193 [2017 Jun;41(3)] Knowledge, Attitude, and Practice of Iranian Intern... 2017-07-06 6,327
192 [2017 Jun;41(3)] Comparison of Antidiabetic Regimens in Patients wit... 2017-07-06 6,408
191 [2017 Jun;41(3)] Diabetes Prevention in Australia: 10 Years Results ... 2017-07-06 6,299
190 [2017 Jun;41(3)] Comprehensive Approach for Managing the Older Perso... 2017-07-06 5,974
189 [2017 Apr;41(2)] A Cutoff for Age at Menarche Predicting Metabolic S... 2017-07-06 5,920
188 [2017 Apr;41(2)] Addition of Ipragliflozin to Metformin Treatment in... 2017-07-06 6,273

목록

Gets the previous 5 pages.   Go to previous page.  [1]   2   3   4   5     Go to next page. Gets the next  5 pages.